Condition Lookup
Category:
Pancreatic Endocrine Disorders
Number of Conditions: 5
Insulinoma
Specialty: Diabetes and Endocrinology
Category: Pancreatic Endocrine Disorders
Sub-category: Hypoglycemia (Non-Diabetes Related)
Symptoms:
episodes of confusion; dizziness; weakness; sweating; palpitations; hunger; blurred vision; loss of consciousness
Root Cause:
A benign tumor of the pancreatic beta cells that produces excessive insulin, causing recurrent hypoglycemia.
How it's Diagnosed: videos
Clinical suspicion based on symptoms, confirmed by a supervised 72-hour fasting test demonstrating hypoglycemia with inappropriately high insulin levels, C-peptide, and proinsulin. Imaging (CT, MRI, or endoscopic ultrasound) is used to localize the tumor.
Treatment:
Surgical removal of the tumor is the primary treatment. In non-surgical cases, medical management focuses on controlling hypoglycemia.
Medications:
Diazoxide (reduces insulin secretion, potassium channel activator) and somatostatin analogs like octreotide (inhibit insulin release).
Prevalence:
How common the health condition is within a specific population.
Insulinomas are rare, with an estimated incidence of 1-4 cases per million people annually.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Associated with multiple endocrine neoplasia type 1 (MEN1) syndrome, though most cases are sporadic.
Prognosis:
The expected outcome or course of the condition over time.
Excellent with surgical removal; the majority of insulinomas are benign and curable. Rare malignant cases may require additional therapies.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Severe recurrent hypoglycemia leading to seizures, neurological damage, or death if untreated.
Reactive Hypoglycemia
Specialty: Diabetes and Endocrinology
Category: Pancreatic Endocrine Disorders
Sub-category: Hypoglycemia (Non-Diabetes Related)
Symptoms:
shakiness; sweating; palpitations; hunger; anxiety; confusion; drowsiness; fatigue
Root Cause:
Excessive insulin release following a meal, leading to a drop in blood glucose levels within a few hours after eating.
How it's Diagnosed: videos
Based on symptoms occurring 2-4 hours post-meal and resolved with carbohydrate intake. Mixed meal tolerance test (MMTT) or continuous glucose monitoring (CGM) may confirm diagnosis.
Treatment:
Dietary modifications, including frequent small meals, low glycemic index foods, and balanced macronutrient intake. In rare severe cases, medications may be used.
Medications:
Acarbose (alpha-glucosidase inhibitor to slow carbohydrate absorption) and in experimental settings, diazoxide to reduce insulin secretion.
Prevalence:
How common the health condition is within a specific population.
Common but underdiagnosed; exact prevalence unknown as many cases are self-limited and not reported.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
History of gastric surgery (e.g., Roux-en-Y gastric bypass), prediabetes, or other conditions affecting glucose metabolism.
Prognosis:
The expected outcome or course of the condition over time.
Typically manageable with dietary adjustments; long-term outcomes are excellent in most cases.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
If untreated, frequent hypoglycemia can lead to weight gain due to compensatory eating and impact quality of life.
Hyperinsulinism
Specialty: Diabetes and Endocrinology
Category: Pancreatic Endocrine Disorders
Symptoms:
hypoglycemia (low blood sugar); dizziness; sweating; shaking; confusion; blurred vision; seizures; loss of consciousness
Root Cause:
Excessive secretion of insulin from the pancreas, often due to a tumor (insulinoma), genetic mutations affecting insulin regulation, or overcompensation for insulin resistance.
How it's Diagnosed: videos
Blood tests (glucose, insulin, and C-peptide levels during hypoglycemia), fasting tests, imaging studies (CT, MRI, or PET scans), and genetic testing in congenital cases.
Treatment:
Dietary management, surgery (if caused by an insulinoma), or medications to regulate insulin secretion.
Medications:
Diazoxide (a potassium channel opener that inhibits insulin secretion) or octreotide (a somatostatin analog to suppress insulin release).
Prevalence:
How common the health condition is within a specific population.
Rare; congenital forms are more common in neonates, while insulinomas occur in about 1-4 per million people annually.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of congenital hyperinsulinism, genetic mutations, or conditions like MEN1 syndrome.
Prognosis:
The expected outcome or course of the condition over time.
Depends on the cause; manageable with treatment but severe hypoglycemia can lead to long-term complications if not addressed.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Recurrent hypoglycemia leading to seizures, brain damage, or developmental delays (in infants).
Glucagonoma
Specialty: Diabetes and Endocrinology
Category: Pancreatic Endocrine Disorders
Symptoms:
skin rash (necrolytic migratory erythema); unexplained weight loss; diabetes; diarrhea; deep vein thrombosis; anemia; glossitis
Root Cause:
Excessive secretion of glucagon due to a tumor in the alpha cells of the pancreas.
How it's Diagnosed: videos
Blood tests (elevated glucagon levels), imaging (CT, MRI, or somatostatin receptor imaging), and biopsy of the tumor.
Treatment:
Surgery to remove the tumor, somatostatin analogs to control symptoms, and supportive care for associated diabetes and nutritional deficiencies.
Medications:
Octreotide or lanreotide (somatostatin analogs that reduce glucagon secretion).
Prevalence:
How common the health condition is within a specific population.
Extremely rare; incidence is estimated at less than 1 per 20 million people annually.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Often occurs sporadically but can be associated with multiple endocrine neoplasia type 1 (MEN1).
Prognosis:
The expected outcome or course of the condition over time.
Poor if left untreated due to the risk of metastasis, but surgical removal can improve outcomes significantly.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Metastatic spread, diabetes, nutritional deficiencies, and thrombosis.
Somatostatinoma
Specialty: Diabetes and Endocrinology
Category: Pancreatic Endocrine Disorders
Symptoms:
diabetes; gallstones; steatorrhea (fatty stools); abdominal pain; weight loss; diarrhea; nausea
Root Cause:
Overproduction of somatostatin, usually due to a rare neuroendocrine tumor in the pancreas or duodenum, leading to inhibition of other hormone secretions.
How it's Diagnosed: videos
Blood tests (elevated somatostatin levels), imaging studies (CT, MRI, or octreotide scans), and biopsy of the tumor.
Treatment:
Surgical resection of the tumor, somatostatin analogs for symptom control, and supportive therapy for nutritional issues.
Medications:
Somatostatin analogs such as octreotide or lanreotide may be used to manage symptoms.
Prevalence:
How common the health condition is within a specific population.
Extremely rare; incidence is estimated to be less than 1 per million people annually.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Often sporadic but may be associated with genetic syndromes like MEN1 or von Hippel-Lindau disease.
Prognosis:
The expected outcome or course of the condition over time.
Variable; early detection and treatment improve outcomes, but metastatic disease has a poor prognosis.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Metastasis, severe malnutrition due to malabsorption, and hormonal imbalances.